MétaCan
Menu
← Back to cohort
Record W2315607170 · doi:10.1158/1538-7445.am2011-2530

Abstract 2530: The anticancer kinase inhibitor dovitinib (TKI258/CHIR258) may have multiple modes of action because it also binds DNA and inhibits topoisomerase I and topoisomerase IIα

2011· article· en· W2315607170 on OpenAlexaffabout
Xing Wu, Jack C. Yalowich, Brian B. Hasinoff

Bibliographic record

VenueCancer Research · 2011
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Treatments and Mutations
Canadian institutionsUniversity of Manitoba
Fundersnot available
KeywordsTopoisomeraseTyrosine kinaseBiologyBiochemistryKinaseMolecular biologyTyrosine-kinase inhibitorFibroblast growth factor receptorDNAReceptorFibroblast growth factorChemistryCancer

Abstract

fetched live from OpenAlex

Abstract Dovitinib (TKI258/CHIR258) is a kinase inhibitor in phase II development for the treatment of renal cell carcinoma, advanced breast cancer, and relapsed multiple myeloma. Dovitinib is thought to exert anticancer effects through its binding to and kinase inhibition of fibroblast growth factor receptor 3 (FGFR3). It also strongly inhibits a number of other kinases that are members of the RTK superfamily, including the vascular endothelial growth factor receptor (VEGFR); fibroblast growth factor receptor 1 (FGFR1); platelet-derived growth factor receptor type 3; FMS-like tyrosine kinase 3 (FLT3); stem cell factor receptor (c-KIT) and colony-stimulating factor receptor 1 (CSF1R) all of which may also contribute to its anticancer activity. In terms of its chemical structure dovitinib is a benzimidazole-quinolinone compound. Thus, structurally it resembles the bisbenzimidazole minor groove binding dye Hoechst 33258. Molecular modeling studies of the docking of dovitinib into an X-ray structure of a Hoechst 33258-DNA complex showed that dovitinib could be reasonably accommodated in the minor groove. Dovitinib was shown to bind to DNA by its ability to increase the DNA melting temperature. Changes in the visible absorbance and fluorescence spectrum of dovitinib that occurred upon addition of DNA were also consistent with DNA binding. Because DNA binders are often topoisomerase I and topoisomerase II inhibitors, the ability of dovitinib to inhibit these DNA processing enzymes was also investigated. Dovitinib inhibited both the decatenation activity and the ATPase activity of topoisomerase IIα in the low micromolar concentration range. Dovitinib was also able to stabilize the topoisomerase IIα-cleavage complex and act as a topoisomerase IIα poison with activity comparable to etoposide as measured by its ability to induce formation of linear DNA. Dovitinib was also examined for its ability to increase phosphorylation of H2AX in K562 cells to determine if it could act as a cellular topoisomerase II poison and induce double strand DNA breaks. Dovitinib was also able to inhibit the topoisomerase I-catalyzed relaxation of DNA. In conclusion, the anticancer activity of dovitinib may result not only from its ability to inhibit multiple kinases, but also from its ability to target topoisomerase I and topoisomerase IIα. Support: CIHR and a Canada Research Chair in Drug Development to BBH and an NIH grant (CA090787) to JCY. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2530. doi:10.1158/1538-7445.AM2011-2530

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.020
Threshold uncertainty score0.066

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0200.004

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.156
GPT teacher head0.441
Teacher spread0.285 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2011
Admission routes2
Has abstractyes

Explore more

Same venueCancer Research→Same topicLung Cancer Treatments and Mutations→French-language works237,207→